Correlation Between Us Strategic and Sarofim Equity
Can any of the company-specific risk be diversified away by investing in both Us Strategic and Sarofim Equity at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Us Strategic and Sarofim Equity into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Us Strategic Equity and Sarofim Equity, you can compare the effects of market volatilities on Us Strategic and Sarofim Equity and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Us Strategic with a short position of Sarofim Equity. Check out your portfolio center. Please also check ongoing floating volatility patterns of Us Strategic and Sarofim Equity.
Diversification Opportunities for Us Strategic and Sarofim Equity
0.88 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between RUSTX and Sarofim is 0.88. Overlapping area represents the amount of risk that can be diversified away by holding Us Strategic Equity and Sarofim Equity in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sarofim Equity and Us Strategic is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Us Strategic Equity are associated (or correlated) with Sarofim Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sarofim Equity has no effect on the direction of Us Strategic i.e., Us Strategic and Sarofim Equity go up and down completely randomly.
Pair Corralation between Us Strategic and Sarofim Equity
Assuming the 90 days horizon Us Strategic Equity is expected to generate 0.89 times more return on investment than Sarofim Equity. However, Us Strategic Equity is 1.12 times less risky than Sarofim Equity. It trades about 0.13 of its potential returns per unit of risk. Sarofim Equity is currently generating about 0.05 per unit of risk. If you would invest 1,327 in Us Strategic Equity on August 31, 2024 and sell it today you would earn a total of 556.00 from holding Us Strategic Equity or generate 41.9% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 99.73% |
| Values | Daily Returns |
Us Strategic Equity vs. Sarofim Equity
Performance |
| Timeline |
| Us Strategic Equity |
| Sarofim Equity |
Us Strategic and Sarofim Equity Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Us Strategic and Sarofim Equity
The main advantage of trading using opposite Us Strategic and Sarofim Equity positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Us Strategic position performs unexpectedly, Sarofim Equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sarofim Equity will offset losses from the drop in Sarofim Equity's long position.| Us Strategic vs. Siit High Yield | Us Strategic vs. Alpine High Yield | Us Strategic vs. Pace High Yield | Us Strategic vs. Fidelity Capital Income |
| Sarofim Equity vs. Aquagold International | Sarofim Equity vs. Morningstar Unconstrained Allocation | Sarofim Equity vs. Thrivent High Yield | Sarofim Equity vs. Via Renewables |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |